U.S. Active Pharmaceutical Ingredient Cdmo Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Active Pharmaceutical Ingredient CDMO Market Outlook
- CMO/CDMO
Global Market
Related Markets
Ask a question about the active pharmaceutical ingredient cdmo market
U.S. active pharmaceutical ingredient cdmo market highlights
- The U.S. active pharmaceutical ingredient cdmo market generated a revenue of USD 38,986.8 million in 2025 and is expected to reach USD 72,649.3 million by 2033.
- The U.S. market is expected to grow at a CAGR of 8.2% from 2026 to 2033.
- In terms of segment, traditional active pharmaceutical ingredient (traditional api) was the largest revenue generating product in 2025.
- Antibody Drug Conjugate (ADC) is the most lucrative product segment registering the fastest growth during the forecast period.
Active pharmaceutical ingredient cdmo market data book summary
| Market revenue in 2025 | USD 38,986.8 million |
| Market revenue in 2033 | USD 72,649.3 million |
| Growth rate | 8.2% (CAGR from 2026 to 2033) |
| Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
| Fastest growing segment | Antibody Drug Conjugate (ADC) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibody Drug Conjugate (ADC), Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API) |
| Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.0% of the global active pharmaceutical ingredient cdmo market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. active pharmaceutical ingredient cdmo market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 72,649.3 million by 2033.
The U.S. holds the largest share in North America’s market and is projected to grow at a significant rate over the forecast period. The country accounted for 97.5% of the market in 2020. Increase in outsourcing practices by pharmaceutical companies and support of CDMOs in reducing operational and capital expenses are responsible for its lucrative growth.
In addition, strong R&D practices in the country and promotion of new therapies have significantly contributed to the considerable market share held by the U.S. Growing number of clinical trials in the country further creates opportunities for active pharmaceutical ingredient CDMOs.
The cost and time involved in offshore production can reduce overall cost-effectiveness and productivity of a manufacturing process. Thus, improved productivity due to domestic manufacturing is anticipated to fuel the market.
No credit card required*
Publish Date: Sep 16, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Active Pharmaceutical Ingredient CDMO Market Scope
Active Pharmaceutical Ingredient CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Recipharm | View profile | 1001-5000 | Jordbro, Stockholms Lan, Sweden, Europe | www.recipharm.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
U.S. Active Pharmaceutical Ingredient CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Active Pharmaceutical Ingredient CDMO Market Outlook will help companies and investors design strategic landscapes.
Traditional Active Pharmaceutical Ingredient (Traditional Api) was the largest segment with a revenue share of 46.36% in 2025.
Horizon Databook has segmented the U.S. active pharmaceutical ingredient cdmo market based on antibody drug conjugate (adc), traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api) covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. holds the largest share in North America’s market and is projected to grow at a significant rate over the forecast period. The country accounted for 97.5% of the market in 2020. Increase in outsourcing practices by pharmaceutical companies and support of CDMOs in reducing operational and capital expenses are responsible for its lucrative growth.
In addition, strong R&D practices in the country and promotion of new therapies have significantly contributed to the considerable market share held by the U.S. Growing number of clinical trials in the country further creates opportunities for active pharmaceutical ingredient CDMOs.
The cost and time involved in offshore production can reduce overall cost-effectiveness and productivity of a manufacturing process. Thus, improved productivity due to domestic manufacturing is anticipated to fuel the market.
- U.S. Active Pharmaceutical Ingredient Cdmo Market Product Outlook (Revenue, USD Million , 2021-2033)
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC
- Others
- U.S. Active Pharmaceutical Ingredient Cdmo Market Synthesis Outlook (Revenue, USD Million , 2021-2033)
- Synthetic
- Biotech
- U.S. Active Pharmaceutical Ingredient Cdmo Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Innovative
- Generics
- U.S. Active Pharmaceutical Ingredient Cdmo Market Workflow Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- U.S. Active Pharmaceutical Ingredient Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular disease
- Diabetes
- Others
Reasons to subscribe to Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Active Pharmaceutical Ingredient CDMO Market Outlook databook
- Our clientele includes a mix of Active Pharmaceutical Ingredient CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Active Pharmaceutical Ingredient CDMO Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Active Pharmaceutical Ingredient CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Active Pharmaceutical Ingredient Cdmo Market, 2021-2033 (US$M)
U.S. active pharmaceutical ingredient cdmo market statistics, by product, 2021-2033 (US$M)
